Genmab A/S reports results for the quarter ended June 30 - Earnings Summary

Genmab A/S

06/08/2026 17:13

Genmab A/S GMAB.CO reported quarterly adjusted earnings of $4.91​​ per share for the quarter ended June 30, lower than the same quarter last year, when the company reported EPS of $5.42.  The mean expectation of ten analysts for the quarter was for earnings of $3.52 per share. Wall Street expected results to range from $2.95  to $4.20 per share.
Revenue rose 24.9% to $1.16 billion from a year ago; analysts expected $1.11 billion. 
Genmab A/S's reported EPS for the quarter was $4.91​.
The company reported quarterly net income of $303 million.
Genmab A/S shares had risen by 5.4% this quarter and lost 6.7% so far this year.
FORECAST CHANGES
The mean earnings estimate of analysts had risen by about 5.8% in the last three months.​ 
In the last 30 days, one analyst negatively revised an earnings estimate
RECOMMENDATIONS
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 16 "strong buy" or "buy," 2 "hold" and 2 "sell" or "strong sell." The average consensus recommendation for the biotechnology & medical research peer group is also "buy" 
Wall Street's median 12-month price target for Genmab A/S is DKK2,300.00, about 17.7% above its last closing price of DKK1,892.00
This summary was machine generated from LSEG data August 6 at 04:13 p.m. UTC. ​All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)
QUARTER ENDING
ESTIMATE 
ACTUAL
BEAT, MET, MISSED
Jun. 30 2026 
3.52
4.91
Beat
Mar. 31 2026 
1.38
0.83
Missed
Dec. 31 2025 
3.43
2.13
Missed
Sep. 30 2025 
4.64
6.46
Beat